EHS
EHS

Lovelace’s Novel Nucleoside LCMS Assay to Be Presented at 12th Workshop on Regulations in Bioanalysis

Increasingly, biopharmaceutical companies are developing nucleoside analogues as chemotherapeutic, anti-bacterial and anti-viral agents.

Of the nucleoside analogues in development, 5-azacytidine is being studied as a targeted therapy for lung cancer, as it may be able to amplify the therapeutic agent at the site of action while reducing off-site toxicities.

The post Lovelace’s Novel Nucleoside LCMS Assay to Be Presented at 12th Workshop on Regulations in Bioanalysis appeared first on Lovelace Biomedical.

EHS
Back to top button